Coronavirus Disease 2019 (COVID-19) in Emergency Medicine
No Results
No Results
processing….
Coronavirus disease 2019 (COVID-19) is the illness associated with the novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus was initially noted during an outbreak of respiratory illness in the population of Wuhan, the capital of Hubei province, China. The first cases were seen in November 2019, with COVID-19 quickly spreading throughout the city. The World Health Organization (WHO) was notified of the outbreak on December 31, 2019. The cases continued to spread outside of the area and then across the world. COVID-19 was reported as a global health emergency by the end of January 2020. As the worldwide case numbers increased, the WHO declared on March 11, 2020, that COVID-19 had reached the pandemic stage. [1]
Infected persons with underlying health conditions seem to be the most vulnerable to succumbing to COVID-19, based on data out of China and Italy. Mortality rates also increase with age, as noted in data from the United States, as well as worldwide. This is related to the fact that persons over age 65 years, but especially those over age 85 years, are more likely to have a severe form of the illness. [2]
The initial stages of COVID-19 infection are nonspecific and include symptoms typical of multiple respiratory illnesses, viral and otherwise. [3, 4]
Viral infections (which may occur simultaneously with COVID-19) in the differential diagnosis include the following [3, 4] :
Bacterial infections in the differential diagnosis include the following [3] :
Atypical pneumonia in the differential diagnosis includes the following [3] :
When individuals contact local emergency services, the 911 Public Safety Answering Points (PSAPs) may ask callers if they are experiencing symptoms of a viral illness. This information is relayed to the responding provider so preparations can be made for an encounter with the patient, which includes donning the appropriate personal protective equipment (PPE). If there is no mention of COVID-19 symptoms by the caller, EMS providers can nonetheless begin their assessment of patients from a safe distance of at least 6 feet once they have arrived on the scene, with PPE worn if symptoms are concerning. Alternatively, agencies may require crews to wear PPE for all responses, regardless of the complaint. Emergency medical services (EMS) medical directors should be involved in this decision and provide guidance. [5]
Standard precautions are recommended on every call. Current recommended PPE for COVID-19 patients includes the following:
If there is a limited supply of PPE, a facemask can be utilized if there are no aerosolizing procedures being performed. Personal glasses are not considered sufficient eye protection. Gowns may also be limited to aerosolizing procedures if there is a shortage. Once treatment is completed and care has been transferred, PPE should be doffed per agency recommendations, and hand hygiene should be performed. [6, 7]
For patients requiring treatment of respiratory symptoms, extreme caution is advised. Aerosolizing procedures are high risk for transmission of COVID-19. An N95 mask, eye protection, and gown should be required by protocols. If possible, aerosolizing procedures should be performed outside of the ambulance prior to transport. High-risk procedures include:
A viral and/or high-efficiency particulate air (HEPA) filter should be applied to tubing for ventilation. If transport is required, family members should not ride in the ambulance. If another person, such as a parent, guardian, or medical aide, is needed in the ambulance, he or she should wear a mask. EMS providers should communicate with the receiving facility regarding suspected COVID-19 patients in order for the facility to prepare infection-control measures. [8]
Since prenotification systems exist in most EMS systems, an emergency department (ED) can be notified when EMS is arriving with a patient suspected of having COVID-19. In addition, hospitals may have a means by which primary care offices or potential patients can let the department know that someone with symptoms will be arriving.
Patients arriving at the ED via EMS may already have had some basic triage performed by EMS providers. Critically ill patients may have already been intubated. Patients with intermediate symptoms may present on BiPAP or nebulizer treatments. Both are aerosolizing procedures that require PPE for the receiving staff members in the ED. A patient should either have the nebulizing treatment stopped before entering the department or be transitioned to a non-rebreather mask. Stable patients may only require a small amount of supplemental oxygen via a nasal cannula.
The more difficult patients to triage are those arriving at the ED independently rather than with EMS personnel. Triage staff should be aware of the possibility that any patient coming through their door may have COVID-19. Appropriate PPE should be worn by those performing triage assessments and vital signs. Patients who are suspected of being infected need to have a mask applied promptly. If a patient’s symptoms and vital signs are concerning, the patient should be brought into the department for further workup, preferably into a room with a door. Individuals who are more stable may be treated in a predesignated area for patients with mild symptoms who have the potential to be discharged home after evaluation. Patients in such an area should still be kept at least 6 feet apart and remain with masks in place while their disposition is determined. [9]
Initially, a travel history was an important factor in determining which patients were at risk for COVID-19. If a patient had recently traveled to China, specifically the Hubei province, the concern was high for a COVID-19 diagnosis. [10] As the virus spread across the world, other countries were added to the travel history, such as Iran and Italy. Now, however, COVID-19 is spread within communities in the United States, with social history having replaced travel history in the workup. Social history should include whether a patient has been in close contact (within 6 feet) with a known positive patient or a patient under investigation for COVID-19. Additionally, employment questions should include whether a patient is a healthcare worker, as such personnel are potentially at higher risk of contracting the disease, depending on their type of work and/or access to PPE.
Reported symptoms of the illness include fever, fatigue, and nonproductive cough. [11] Other symptoms reported are body aches, shortness of breath, and diarrhea. New symptoms are continuing to be investigated and may include anosmia and dysgeusia. Patients are reporting onset of symptoms over a period of a week, with rapid progression to respiratory distress around day 8.
Severe conditions that patients with COVID-19 have presented with include septic shock, diabetic ketoacidosis, acute kidney injury, acute cardiac injury, and dysrhythmias. [12, 13]
A patient’s age and comorbidities are a valuable part of history, with elderly patients, especially those with multiple comorbidities, having higher rates of complications and death. [14] Once patients are admitted to the hospital, there will be more time to obtain additional history. In addition, a patient’s family may be able to provide more information regarding travel, social, and medical history.
Evaluation of vital signs will provide some initial information regarding a possible infection. A high fever may be present, but some patients develop only a low-grade fever when infected. Tachycardia can accompany a fever and may be present in the early stages of shock. Tachypnea can indicate the beginning of respiratory distress. In addition, a pulse oximeter can be used to catch a COVID-19 infection, as many patients have been found on initial assessment to be hypoxic. [15]
Further evaluation of a patient suspected to have COVID-19 infection should be conducted in a private room, preferably one employing negative pressure. The examiner should be dressed with PPE for droplet precautions, including mask, eye protection, gown, and gloves. The remainder of a typical physical exam on a COVID-19–infected patient may reveal increased work of breathing using accessory muscles, circumoral cyanosis, and/or confusion from hypoxia. Lung sounds initially are unremarkable, but the patient can develop a mild expiratory wheeze.
As the disease progresses, fine crackles can be heard, as in early pneumonia. Once a patient has developed acute respiratory distress syndrome (ARDS), course rales and diffuse rhonchi are heard. [12]
The physical exam will continue to evolve throughout the course of the illness. As an inpatient, repeat examinations will help to assess if the patient is progressing to a more critical state. Much of the physical exam, both in the ED and during hospitalization, can be performed by merely observing the patient for outward signs of disease—ie, increased work of breathing, retractions, tachypnea, and diaphoresis—in addition to the aforementioned evaluation of vital signs.
Current recommendations regarding viral testing for COVID-19 are based on a patient being symptomatic, having had close contact with a known positive patient, or living in or having engaged in recent travel to an area with high community transmission. Employment as a healthcare worker is another indication for such testing. Priority testing is aimed at hospitalized patients and healthcare workers. The next highest priority are symptomatic patients in long-term care facilities, patients over age 65 years, those with underlying conditions, and first responders. Persons who are not symptomatic may also be considered for testing if supplies allow. [16] In addition, viral respiratory testing can be considered based on regional prevalence of COVID-19. Although viral testing for influenza, respiratory syncytial virus, and rhinovirus may also be available, co-infection may be seen with these disorders, and therefore, positive results for these conditions would not rule out COVID-19.
SARS-CoV-2 tests can performed on a sample—collected, for example, via a nasopharyngeal, oropharyngeal, nasal midturbinate, or anterior nares swab—using a reverse-transcription polymerase chain reaction (RT-PCR) assay. [17, 18] Unfortunately, current COVID-19 testing is showing variable rates of false negatives. Repeat testing can be performed if there is still a concern regarding diagnosis. Samples from sputum or bronchial lavage are thought to be more accurate than a nasopharyngeal swab. [19]
Other laboratory testing may be indicated, as a variety of abnormalities are being found in COVID-19–infected patients. Most of these tests, however, are more useful for hospitalized patients. The tests may be trended and may indicate whether a patient is either improving or progressing to a more critical state. As may occur in other infections, leukopenia and leukocytosis are common in COVID-19. Other patients have had elevations of liver enzymes, muscle enzymes, C-reactive protein, lactate dehydrogenase, and ferritin. [11, 15] While D-dimer remains a debatable test, it has been found to be elevated in patients with higher rates of ARDS and death. [20]
Chest radiography is a typical initial imaging study for patients with respiratory symptoms. In COVID-19, a plain chest film may show peribronchial thickening, as is typical in a viral illness; pulmonary infiltrates, which are also seen in pneumonia; or no obvious findings at all.
However, providers concerned about a diagnosis of COVID-19 tend to perform chest computed tomography (CT) scanning, since this seems to support a more definitive diagnosis. [21] (A patient infected with COVID-19 pneumonia will likely show ground-glass opacities, usually in the lower lobes, although these can also be seen throughout the lungs. [22] ) Nonetheless, chest CT scanning is recommended for patients who are being hospitalized and not as a first-line diagnostic tool. [23] If a patient continues to worsen, a chest CT scan may be indicated to further evaluate the individual’s pulmonary status.
Patients with only mild symptoms of fever, cough, and/or body aches are likely to be discharged from the ED rather than require admission, since treatment at home tends to be sufficient. Patients may use over-the-counter medications for symptomatic relief, including antipyretics, analgesics, and cough medications, along with oral hydration. Infected patients should isolate themselves from others in their home as much as possible, [24] and common areas should frequently be disinfected to reduce the risk of virus spread. If an infected patient must leave home, he or she should wear a facemask in order to protect others from infection.
Patients with COVID-19 who require hospitalization are typically in need of respiratory support. In the ED, such support may mean only a need for oxygen via a nasal cannula, while other patients may be in respiratory arrest, requiring intubation and mechanical ventilation. Aerosol-generating procedures, such as high-flow oxygen and noninvasive positive-pressure ventilation, are high risk for healthcare providers, and strict isolation precautions should be taken. Nebulized medications can be considered in patients with acute bronchospasm who have a known diagnosis of asthma or chronic obstructive pulmonary disease (COPD). Otherwise, these agents have not been found to be useful and come with a high level of risk to providers. [25]
If quick improvement is not seen, more aggressive measures should be considered. While in the ED, aggressive treatment would likely include preparation for mechanical ventilation. Intubation would typically be performed with the use of rapid sequence intubation, preferably by the most qualified provider. When preoxygenating via bag-valve-mask ventilation or CPAP, precautions must be taken because both are considered aerosolizing procedures. Video laryngoscopy can aid in increasing the distance between the provider and the patient during intubation.
A viral filter needs to be placed in the airway circuit once an endotracheal tube has been inserted. After the patient has been intubated, admission to the hospital will be required. Once the individual has been admitted, intensivists can work to manage the patient’s care. [26, 27] .
It should be noted that there are no definitive pharmacologic treatments for COVID-19.
Overview
What are the differential diagnoses of coronavirus disease 2019 (COVID-19)?
What are the potential symptoms of coronavirus disease 2019 (COVID-19)?
What are the severe complications and comorbidities of coronavirus disease 2019 (COVID-19)?
What are the initial vital signs in typical patients with coronavirus disease 2019 (COVID-19)?
What are the physical findings of coronavirus disease 2019 (COVID-19) pneumonia and ARDS?
What are the current recommendations regarding lab testing for coronavirus disease 2019 (COVID-19)?
What types of collection samples can be used for coronavirus disease 2019 (COVID-19) testing?
What lab abnormalities are typically found in coronavirus disease 2019 (COVID-19)?
How is mildly symptomatic coronavirus disease 2019 (COVID-19) treated in the emergency department?
How is severe coronavirus disease 2019 (COVID-19) treated in the emergency department?
World Health Organization. Coronavirus disease (COVID-19) Pandemic. WHO. Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed: April 8, 2020.
CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 – United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 3. 69 (13):382-386. [Medline]. [Full Text].
Prasad P, Goldsmith L, Ingerowski E. COVID-19. visualDX. Available at https://www.visualdx.com/visualdx/diagnosis/covid-19?moduleId=101&diagnosisId=56622. 2020 Mar 16; Accessed: April 8, 2020.
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls. 2020 Jan. [Medline]. [Full Text].
[Guideline] Centers for Disease Control and Prevention. Interim Guidance for Emergency Medical Services (EMS) Systems and 911 Public Safety Answering Points (PSAPs) for COVID-19 in the United States. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-for-ems.html. 2020 Mar 10; Accessed: April 8, 2020.
Pennsylvania Department of Health. Suspected Influenza-Like Illness (ILI) Statewide BLS Protocol. Special Considerations. Available at https://www.health.pa.gov/topics/Documents/EMS/Protocol%20931%20Suspected%20Influenza-Like%20Illness.pdf. 2020 Mar 16; Accessed: April 8, 2020.
New Hampshire Department of Safety. Emergency Protocol – COVID-19. Available at https://www.nh.gov/safety/divisions/fstems/documents/covid19protocol.pdf. Accessed: April 8, 2020.
Northeast Ohio Regional EMS. COVID‐19 Respiratory Distress Supplement. Available at http://cecoms.cuyahogacounty.us/pdf/CovidTransportProtocol.pdf. 2020 Apr 3; Accessed: April 8, 2020.
Centers for Disease Control and Prevention. Triage of Suspected COVID-19 Patients in non-US Healthcare Settings. Coronavirus Disease 2019 (COVID-19). Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/non-us-settings/sop-triage-prevent-transmission.html. 2020 Mar 27; Accessed: April 8, 2020.
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15. 395 (10223):507-513. [Medline]. [Full Text].
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15. 395 (10223):497-506. [Medline]. [Full Text].
Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Feb 7. [Medline]. [Full Text].
Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020 Mar 26. 368:m1091. [Medline]. [Full Text].
McIntosh K, Hirsch MS, Bloom A. Coronavirus disease 2019 (COVID-19). UpToDate. 2020 Apr 7. [Full Text].
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24. [Medline]. [Full Text].
Centers for Disease Control and Prevention. Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19). Coronavirus Disease 2019 (COVID-19). Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html. 2020 Mar 14; Accessed: April 8, 2020.
Patel A, Jernigan DB, 2019-nCoV CDC Response Team. Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak – United States, December 31, 2019-February 4, 2020. MMWR Morb Mortal Wkly Rep. 2020 Feb 7. 69 (5):140-6. [Medline]. [Full Text].
Centers for Disease Control and Prevention. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19. Coronavirus Disease 2019 (COVID-19). Available at https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html. Reviewed May 22, 2020; Accessed: June 9, 2020.
Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020 Mar 11. [Medline]. [Full Text].
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15. 395 (10223):507-13. [Medline]. [Full Text].
Li Y, Xia L. Coronavirus Disease 2019 (COVID-19): Role of Chest CT in Diagnosis and Management. AJR Am J Roentgenol. 2020 Mar 4. 1-7. [Medline]. [Full Text].
Bai HX, Hsieh B, Xiong Z, et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology. 2020 Mar 10. 200823. [Medline]. [Full Text].
American College of Radiology. ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection. ACP Position Statements. Available at https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection. 22 Mar 2020; Accessed: April 8, 2020.
World Health Organization. Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts. WHO. Available at https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts. 17 Mar 2020; Accessed: April 8, 2020.
Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). Coronavirus Disease 2019 (COVID-19). Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. 2020 Apr 6; Accessed: April 8, 2020.
World Health Organization. Severe Acute Respiratory Infections Treatment Centre. WHO. Available at https://www.who.int/publications-detail/severe-acute-respiratory-infections-treatment-centre. 2020 Mar 28; Accessed: April 8, 2020.
[Guideline] Alhazzani W, Moller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020 Mar 28. [Medline]. [Full Text].
Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Johns Hopkins University & Medicine. Available at https://coronavirus.jhu.edu/map.html. Accessed: April 21, 2020.
Washington Post Staff. Mapping the worldwide spread of the coronavirus. The Washington Post. April 21, 2020. Available at https://www.washingtonpost.com/graphics/2020/world/mapping-spread-new-coronavirus/.
Hernandez S, O’Key S, Watts A, Manley B, Pettersson H. Tracking Covid-19 cases in the US. CNN. 2020 April 01. Available at https://www.cnn.com/interactive/2020/health/coronavirus-us-maps-and-cases/.
Gilead Sciences. Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV). Available at https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-the-company-ongoing-response-to-the-2019-new-coronavirus. 31 Jan 2020; Accessed: April 8, 2020.
Centers for Disease Control and Prevention. Information for Clinicians on Therapeutic Options for Patients with COVID-19. Coronavirus Disease 2019 (COVID-19). Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html. 2020 Apr 7; Accessed: April 8, 2020.
Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 Mar 27. [Medline]. [Full Text].
Melissa Kohn, MD, MS, FACEP, EMT-PHP Clinical Instructor of Emergency Medicine, Sidney Kimmel Medical College of Thomas Jefferson University; Emergency Medicine/EMS Physician, Director of EMS Resident Education, Medical Command Facility Director, Einstein Medical Center
Melissa Kohn, MD, MS, FACEP, EMT-PHP is a member of the following medical societies: American College of Emergency Physicians, National Association of EMS Physicians
Disclosure: Nothing to disclose.
Coronavirus Disease 2019 (COVID-19) in Emergency Medicine
Research & References of Coronavirus Disease 2019 (COVID-19) in Emergency Medicine |A&C Accounting And Tax Services
Source
0 Comments